A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
Phase 1 Terminated
5 enrolled
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Phase 1/2 Terminated
3 enrolled 10 charts
Safety Study of MGD009 in B7-H3-expressing Tumors
Phase 1 Terminated
67 enrolled
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
Mithramycin for Lung, Esophagus, and Other Chest Cancers
Phase 2 Terminated
16 enrolled 13 charts
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
Phase 1 Terminated
23 enrolled
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Phase 1 Terminated
44 enrolled
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase 1/2 Terminated
15 enrolled 14 charts
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Phase 1 Terminated
17 enrolled